On July 8, Sino Biopharmaceutical rose 3.73% in regular trading, trading at HK$5.01 per share, with turnover of HK$82.34 million.

On the news front, the company announced that its subsidiary Chia Tai Tianqing Pharmaceutical Group has entered into an exclusive licensing agreement with AstraZeneca for its self-developed PDE3/4 inhibitor TQC3721. Under the agreement, Sino Biopharmaceutical grants AstraZeneca exclusive rights to develop, manufacture, and commercialize TQC3721 outside China, along with a global exclusive license for specific development programs. The company will receive a $200 million upfront payment, with potential development, regulatory, and sales milestone payments totaling up to $1.9 billion, plus tiered royalties of up to double-digit percentages based on annual net sales.

This marks the companys second licensing deal with a multinational pharmaceutical firm this year, following a collaboration with Sanofi in February. AstraZeneca, a global leader in respiratory medicine, is expected to leverage its clinical expertise to accelerate TQC3721s global development as a potential best-in-class therapy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)